AbbVie (ABBV) has been under pressure recently, with the share price showing a 5.2% decline over the past day and an 8.5% drop over the past week, closing at US$208.34. Short term weakness has also ...

AbbVie’s model based fair value has been adjusted only slightly, moving from US$248.29 to US$248.86, which keeps the overall ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson’s Icotyde, the first oral IL-23 inhibitor on the market. This ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

AbbVie (ABBV) dropped 4.69% after FDA approved J&J's Icotyde psoriasis pill, creating fresh competition for blockbuster drug ...

Is ABBV a good stock to buy? We came across a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was trading at ...

The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

AbbVie’s stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq ...